<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011386</url>
  </required_header>
  <id_info>
    <org_study_id>MANGO</org_study_id>
    <nct_id>NCT02011386</nct_id>
  </id_info>
  <brief_title>Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis</brief_title>
  <acronym>MANGO</acronym>
  <official_title>Improved Monitoring and Prediction of Clinical Response and Disease Course During Golimumab Therapy of Patients With Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Mikkel Østergaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates different criteria for remission based on MRI and circulating
      biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with
      axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates
      factors that affect disease activity, function and participation by use of different
      questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fulfillment of Bath Ankylosing Spondylitis (BASDAI50) (i.e. reduction of 50%)</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI assessment (score)</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients with Ankylosing Spondylitis Disease Activity Score (ASDAS response)</measure>
    <time_frame>Week 16 and 52</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>Treatment: Injection Golimumab 50 mg every month on the same date</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Treatment: Injection Golimumab 50 mg every month on the same date</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with axial spondyloarthritis with moderate to high disease activity (BASDAI &gt;= 40
        mm), who are going to start treatment with tumor-necrosis-factor-alpha inhibitor.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Axial spondyloarthritis according to the ASAS classification criteria

          -  Sacroiliitis on conventional X-rays or MRI.

          -  Disease activity assessed by BASDAI &gt;40 mm despite treatment with NSAID.

          -  Clinical indication for tumor-necrosis-factor-alpha inhibitor treatment by the
             treating physician.

        Exclusion Criteria:

          -  No contraindications for tumor-necrosis-factor-alpha inhibitor

          -  No contraindications for MRI

          -  No contraindications in participation in a study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Østergaard, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frederiksberg Bispebjerg Hospitals, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital, Dep. of Radiology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital Hillerød, Dep. of Rheumatology</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Køge Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>January 4, 2019</last_update_submitted>
  <last_update_submitted_qc>January 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Professor Mikkel Østergaard</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 26, 2020</submitted>
    <returned>June 17, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

